LGC acquires DiaMex to drive innovation and choice for core laboratory customers: Acquisition complements LGC’s serology and molecular quality control portfolio and enhances choice of products from a single supplier

London, UK – 4 December 2024 – LGC today announces an addition to its growing global clinical diagnostics and genomics portfolio, following the acquisition of DiaMex, a manufacturer of third-party serology and molecular quality controls used in clinical laboratories and blood banks across the world.

Focused on providing the highest quality controls, DiaMex has a long history of successful product development and growth in cooperation with strategic partners. Over the past thirteen years, they have provided customers with a comprehensive portfolio of third-party serology controls, and, more recently, also developed and commercialized molecular controls.

Ken Yoon, Executive Vice President and General Manager of LGC’s Diagnostics & Genomics Business Unit commented: “By acquiring DiaMex, we will now have access to a best-in-class product range (Optitrol) that complements our own quality control portfolio. This will greatly enhance the choice of products we can offer our customers within the core laboratory and blood bank spaces, helping us to drive stronger partnerships together, particularly for our clients in Europe, Asia Pacific, and Latin America.”

“As we continue to seek opportunities to strengthen the portfolio of in vitro diagnostics serology and molecular controls we can offer our clinical laboratory customers, we are delighted to welcome DiaMex to the LGC family. This acquisition will enable us to drive innovation forward much more rapidly and give us a highly differentiated product portfolio.” said Bharathi Anekella, Executive Vice President and leader of LGC’s Diagnostics & Genomics Innovation Hub.

About LGC
LGC is a global leader in life science tools, dedicated to partnering with customers to deliver solutions that diagnose, treat, feed, and protect our growing population. With over 180 years of scientific heritage, we collaborate with the scientific community to tackle some of the world’s most complex challenges, responding to global health crises, pioneering precision medicine, and enhancing the safety of food, medicines, and the environment.

Operating in 14 countries, LGC’s products and services are integral to industries that safeguard public health, food, water, and medicine. Our solutions help our diverse customer base—from pharmaceutical companies and diagnostic manufacturers to testing laboratories
and food producers—maintain the highest standards of quality, safety, and compliance.

Together with our partners, we work toward a safer, healthier, and more sustainable world, advancing the science that protects people and the planet. For further information visit: www.lgcgroup.com

Customer contact:
Brian Boissonneault, VP, Product Management, LGC Diagnostics & Genomics
brian.boissonneault@lgcgroup.com
+1 720 572 8344

Media contacts:
Edel McCaffrey, Head of Corporate Communications, LGC Group
edel.mccaffrey@lgcgroup.com
+44 7587 315 615

Andrew Thomas, LGC Group Corporate Communications
andrew.thomas@lgcgroup.com
+44 7803 585 254